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Beta-Adrenergic Blocking Agents in Congestive Heart Failure 
Sidney Goldstein, MD' 
Although recent physiologic studies suggest that increased catecholamine release in humans may in 
the long run represent an adverse homeostatic mechanism, this catecholamine release is acutely 
important in permitting human response to stress. Clinical interventions with beta-adrenergic 
blocking agents have showed a salutary effect on cardiac function in patients with severe heart failure: 
in patients with heart failure associated with myocardial infarction, these agents may help improve 
mortality rates. These studies indicate that the drugs are well tolerated when used carefully in these 
high-risk patients. (Henry Ford Hosp Med J 1986:34:184-7) 
R ecent clinical investigations suggest that beta-adrenergic blocking agents may have a beneficial role in the treatment 
of patients with heart failure. This appears paradoxical, since 
this class of drugs has long been known to have a negative 
inotropic effect. Nevertheless, a series of clinical studies sug-
gests that these agents may be effective in certain patients with 
heart failure. Investigations have been canied out in two groups 
of patients: those with heart failure due to primary cardiomyopa-
thy (1-5), and those who experience heart failure in association 
with a recent acute myocardial infarction (6-8). The investiga-
tions of beta-adrenergic blocking agents in primary cardio-
myopathy have examined patients' physiologic responses to 
these drugs. Since the number of patients available for such 
studies is limited, information is not yet available regarding the 
long-term effect of beta-blocking agents on mortality. Clinical 
trials, however, are planned to explore this issue. Conversely, 
patients with recent myocardial infarction associated with heart 
failure were studied not only to examine the effects of these 
dmgs on morbidity and mortality but also to determine whether 
adverse dmg reactions occuned. 
Norepinephrine in Heart Failure 
These clinical studies, coupled with the observation that the 
mortality rate of heart failure appears to be directly related to 
norepinephrine concentration (9), have not only encouraged in-
vestigation of the neurohumoral response to heart failure but 
also increa.sed our understanding of norepinephrine and its role 
in heart failure. Although it was recendy observed that plasma 
norepinephrine concentration is increased in patients with heart 
failure, we have known for some time that the concentration of 
catecholamine in the myocardium is decreased (10-12). 
These observations suggest that myocardial norepinephrine 
uptake is decreased or that the rate of norepinephrine turnover 
or clearance in the failing myocardial tissue is accelerated. The 
reflex-neurohumoral response to heart failure is usually accom-
panied by norepinephrine release. In the setting of a falling car-
diac output, norepinephrine maintains systemic blood pressure 
by vasoconstriction. The decreased myocardial catecholamine 
concentration is thought to be caused by chronic increased sym-
pathetic discharge which is required for the maintenance of 
blood pressure. The decreased myocardial norepinephrine con-
centration resuldng from the chronic neurosympathetic activity 
may explain the myocardial beta-adrenergic receptor down-
regulation (13). This down-regulation of beta-receptors partly 
explains the failure of the myocardium to respond to increased 
norepinephrine concentration in the blood. Studies of nor-
epinephrine clearance in patients with heart failure indicate that 
the increased semm norepinephrine content is a function of both 
increased norepinephrine release and a decrease in regional nor-
epinephrine clearance in the specific coronary vascular bed (14). 
This combination of increa.sed norepinephrine secretion and de-
creased clearance is observed in cardiac and renal beds but not in 
the pulmonary bed. Although increased norepinephrine is criti-
cal to the eariy adaptation to a fall in cardiac output, in the long 
mn beta-receptor down-regulation and decreased clearance of 
norepinephrine render adrenergic stimulation less important for 
the maintenance of cardiac homeostasis. In fact, increased 
semm norepinephrine concentration may be detrimental to car-
diac function, leading to increased work load of the heart result-
ing from alpha-receptor stimulation and increased systemic 
vascular resistance. Continued myocardial stimulation may also 
lead to acceleradon of myocardial degeneration (15), promoting 
cardiac anhythmias and sudden death (16). 
The relationships between circulatory and myocardial nor-
epinephrine, beta-receptor regulation, and cardiac function at 
rest and during stress are shown in Figs 1 and 2. In the setting of 
heart failure, an increase occurs in circulating norepinephrine 
stores. This increase in circulatory norepinephrine results in an 
increased peripheral resistance in the setting of decreased left 
ventricular function (Fig I). With stress in the failing heart, a 
Submitted for publication: July 8, 1986. 
Accepted for publication: July 28. 1986. 
'Heart and Vascular Institute, Division of Cardiovascular Medicine. Henry Ford 
Hospital. 
Address correspondence to Dr Goldstein, Division of Cardiovascular Medicine, Henry 
Ford Hospital, 2799 W Grand Blvd, Detroit, Ml 48202. 
184 Henry Ford Hosp Med J—Vol 34, No 3, 1986 Beta-Blocking Agenis—Goldstein 
REST 
Per iphera l Systemic 
Receptors Res i s -
tance 
Cardiac LV 
NE 
Stores 
p Receptor 
Regula t ion Fx Card iac NE 
Sto res 
P Receptor 
Regula t ion 
HEART FAILURE 
Fig I—The relationship between circulatory norepinephrine (NE), beta-receptor regula-
tion, peripheral resistance, and left ventricular function (LV Ex) in the normal individual 
and the individual with heart failure. 
slight increase in left ventricular function occurs as a result of a 
marked increase in circulating norepinephrine, but is associated 
with a further exaggeration of systemic resistance (Fig 2). 
Beta Blockers in Cardiomyopathy 
The seminal clinical studies by Waagstein et al (I), in which 
metoprolol was administered to patients having heart failure 
predominantly due to primary cardiomyopathy, first explored 
the potential of this therapy. Most recently, Engelmeier and col-
leagues (4) examined the effect of graded doses of metoprolol on 
cardiac function in patients with primary cardiomyopathy. In-
cremental doses of metoprolol were carefully administered to 
patients up to when either the daily dose of 100 mg was reached 
or a systolic pressure of 90 mm Hg or a pulse rate of 60 was 
achieved. The endpoints of therapy were attained in 20 of 21 
patients. 
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Fig 2—Similar relationship of normal individual and heart failure individual during stress. 
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Table 
Efficacy of Beta-Blocking Agents in Heart Failure 
No. of Tolal Death Sudden Death 
Study Drug Patients Placebo Control Placebo Control 
Hansteen et al (6) Propranolol 560 13.1% 9.0% 8.2% 4,0% 
Australian/ 
Swedish 
study(7) Pindolol 529 17.7% 17.1% 11.7% 10.6% 
Beta Blocker 
Heart Attack 
Trial subgroup 
analysis(l) Propranolol 710 18.4% 13.3% 10.4% 55.5% 
Once metoprolol dosage was established, 14 of the 20 patients 
experienced improved exercise tolerance, and seven of 20 
achieved an improvement in ejection fraction and fall of the left 
ventricular end-diastolic pressure to almost normal levels. The 
changes took place over a three-month period. Only rare, ad-
verse effects that could not be dealt with by prolongation of dos-
age interval were observed. The effect of the drug appeared to be 
closely related to its bradycardic effect. Similar results were re-
ported by Svedberg et al (2). Other studies of mixed patient pop-
ulations with heart failure due to diverse causes failed to show a 
beneficial effect of metoprolol when changes were measured 
within one month (3,5). Engelmeier et al (4) suggest that the ef-
fect of metoprolol requires treatment for a longer duration. 
These studies suggest that beta-adrenergic blocking agents 
may produce a beneficial effect in heart failure patients. Patient 
candidates include those with tachycardia and perhaps hyper-
tension. The only drug used in these treatment programs was 
metoprolol, a cardioselective drug. A case can be made that 
these should be the most appropriate beta blockers to use, since 
the increased vasoconstriction occasionally observed with non-
selective dmgs could modify the effects of these drugs. The ef-
fects of these dmgs which also result in alpha-blockade may also 
be modified by decreasing peripheral resistance. 
Beta-Blocking Agents in Congestive Heart Failure 
Associated with Coronary Heart Disease 
The results of beta blocker studies in postinfarction patients 
with heart failure are listed in the Table, The two prospective 
studies were not specifically designed to study the effect of these 
agents in postinfarction patients with heart failure alone, A Nor-
wegian study (6) and a combined Australian/Swedish study (7) 
examined high-risk postmyocardial infarction individuals in 
whom heart failure was one of the major characteristics. Also 
included in these study populations, however, were patients with 
ventricular ectopy and serious cardiac rhythm disturbances. The 
Norwegian study of high-risk postmyocardial infarction patients 
observed that total and sudden death mortality decreased to 32% 
(p value not significant) and 50% (p < 0,05) when patients were 
treated with propranolol. In the combined Australian/Swedish 
multicenter study with pindolol, no significant beneficial effect 
was observed in patients treated with that beta blocker This lack 
of effect may be attributed to the intrinsic sympathomimetic-
stimulating activity characteristics of pindolol. The incidence of 
heart failure in the active treatment program in both studies was 
slightly higher than in the placebo group. In the Norwegian pro-
pranolol study, the occunence of heart failure in the first two 
weeks of therapy was 6.5% in the propranolol group and 1.8% in 
the placebo group. After two weeks this adverse effect related to 
propranolol disappeared and was 1.4% in the propranolol group 
and 3.9% in the placebo group. 
A retrospective subgroup analysis was conducted in the Beta 
Blocker Heart Attack Trial (8), examining patients who had ex-
perienced congestive heart failure priorto randomization. In 
this ix)stmyocardial infarction study, the total mortality over the 
25-month average follow-up in the patients with heart failure 
treated with propranolol was 13.3% compared to 18.4% in the 
placebo group; in those without heart failure, the mortality was 
5.9% and 7.8%. The decrease in total mortality, 27% and 25%, 
respectively, was similar regardless of the history of heart 
failure. Patients with heart failure, however, did experience a 
greater absolute benefit with beta blockers because of the in-
crease in mortality rate in general. An impressive 47% decrease 
in the rate of sudden death was observed in the propranolol-
treated patients with a history of heart failure, compared to a 
13% decrease in those without heart failure. However, a slight 
increase of heart failure did occur during the first 30 days of pro-
pranolol administration in patients having a history of heart 
failure. The overall incidence of heart failure during follow-up 
was similar in the placebo-treated and propranolol-treated pa-
tients regardless of whether they had previous heart failure. 
The mechanism by which beta blockers modify mortality in 
coronary heart disease patients is not entirely clear Patients with 
heart failure are known to have increased ventricular ectopy. 
In the Beta Blocker Heart Attack Trial (8), 19.6% of the pa-
tients with a history of heart failure had > 10 ventricular prema-
ture beats/hr compared to 11,8% of those without a history of 
heart failure, A similar increased frequency of ventricular com-
plex ectopy was observed in padents with heart failure (50,2%) 
compared to those without a history of heart failure (38,6%) 
(p < 0,05). Beta blockers have been shown to decrease ven-
tricular ectopy in patients with coronary heart disease. This 
particular effect may explain the observed decrease in total 
mortality, particularly in view of the decreased rate of sudden 
death in propranolol-treated patients. However, whether this de-
creased frequency of ventricular ectopy is an antiarrhythmic 
effect or is due to the ability of beta blockers to modulate myo-
cardial ischemia is unclear. Antiarrhythmic effects of beta 
blockers have been demonstrated in patients without ischemic 
heart disease (17). In animal models, beta blockers have been 
shown to decrease ventricular fibrillation threshold in both is-
chemic and nonischemic animals (18). 
Engelmeier et al (4) suggest a number of other possible mech-
anisms by which beta-adrenergic blocking dmgs can exert their 
action. They suggest that these dmgs may block the cardiotoxic 
effects of catecholamines, restore the down-regulation of beta-
adrenergic receptors, or modulate inappropriate tachyar-
rhythmias. The restoration of normal receptor regulation occurs 
as a result of chronic beta-receptor blockade, rendering these 
receptors more sensitive to beta stimulation. Regardless of 
the proposed mechanism, the demonstration of their clinical 
186 Henry Ford Hosp Med J—Vol 34, No 3, 1986 Beta-Blocking Agents—Goldstein 
efficacy has stimulated considerable research on how these 
dmgs can modify both symptomatology and mortality. 
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